INNORNA Completes Phase II Enrollment for Bivalent RSV mRNA Vaccine IN006

Innorna has completed enrollment and vaccination in its Phase II clinical trial for IN006, a bivalent RSV mRNA vaccine. The trial marks a milestone toward dose optimization and sets the stage for Phase III efficacy studies. IN006 is a first-in-class RSV vaccine developed in China, targeting RSV-A and RSV-B. The vaccine has shown a favorable safety profile and strong immune responses in preclinical studies, and is aimed at addressing the need for effective prevention against RSV, which poses significant health risks to older adults and young children.

GSK (GlaxoSmithKline) has announced that its RSV vaccine, Arexvy, will be offered through select provincially funded programs to help prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) among eligible Canadian adults. This move follows the March 2025 update from the National Advisory Committee on Immunization (NACI), which recommends RSV vaccination for adults aged 75 and older, as well as those aged 60 and above residing in nursing homes or other chronic care facilities. Adults aged 50 to 74 are advised to consider vaccination in consultation with their healthcare provider GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada^[1].

Arexvy, approved in Canada for the prevention of LRTD caused by RSV in adults 60 years of age and older, and in adults 50 through 59 years of age who are at increased risk for RSV disease, is set to account for the majority share of publicly funded RSV vaccine doses provided in the country for 2025-2026. The vaccine, which contains recombinant glycoprotein F stabilized in the prefusion conformation (RSVPreF3) combined with GSK's proprietary AS01E adjuvant, is designed to address the significant health risks posed by RSV, particularly for older adults and young children GSK’s RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada^[2].

The inclusion of Arexvy in publicly funded immunization programs aims to enable broader access to an important vaccine for older Canadians who are among those at increased risk for severe RSV disease. GSK is committed to collaborating with public health partners across the country to expand access to Arexvy and help ensure that vulnerable Canadians can be protected against the virus and its complications GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada^[1].

Adults aged 50 and older who are not eligible for vaccination against RSV as part of a publicly funded program can access Arexvy at pharmacies across Canada, with a prescription from their primary care provider typically required GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada^[1].

The decision to include Arexvy in publicly funded programs underscores the growing recognition of the importance of RSV vaccination in Canada. With the aging population and the increased risk of respiratory virus infections during the fall and winter months, vaccination against RSV can reduce hospitalizations and safeguard the health and independence of seniors across the country GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada^[1].

In parallel, Innorna, a biopharma company based in China, has completed enrollment and vaccination in its Phase II clinical trial for IN006, a bivalent RSV mRNA vaccine. The trial marks a milestone toward dose optimization and sets the stage for Phase III efficacy studies. IN006 is a first-in-class RSV vaccine targeting RSV-A and RSV-B, showing a favorable safety profile and strong immune responses in preclinical studies. This development further highlights the global effort to address the need for effective prevention against RSV .

The integration of Arexvy into public health programs and the progress of IN006 underscore the industry's commitment to combating RSV, a significant health concern, particularly for vulnerable populations. Investors and financial professionals should closely monitor these developments, as they reflect the growing market demand for RSV vaccines and the potential for these products to improve public health outcomes.

References:
GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada^[1] GSK’s RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada (CNW Group/GlaxoSmithKline Inc.)
GSK’s RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada^[2] Biospace - GSK's RSV Vaccine Arexvy Included in Publicly Funded Prevention Programs for Older Adults in Canada
Innorna Completes Phase II Clinical Trial for IN006 RSV mRNA Vaccine